Manuscripts
Showing 1530 manuscripts.
Genetic complexity in the replication-competent latent HIV reservoir increases with untreatedinfection duration in infected youth
Citation
ZL Brumme, H Sudderuddin, C Ziemniak, K Luzuriaga, BR Jones, JB Joy, CK Cunningham, T Greenough, D Persaud. Genetic complexity in the replication-competent latent HIV reservoir increases with untreatedinfection duration in infected youth. AIDS. 2019. 33: 211-218. PMID: 30325763Year
2019
Journal
AIDS
Study
P1059
Adverse Pregnancy Outcomes Among Women Who Conceive on Antiretroviral Therapy
Citation
Risa M Hoffman, Sean S Brummel, Paula Britto, Jose H Pilotto, Gaerolwe Masheto, Linda Aurpibul, Esau Joao, Murli U Purswani, Shelley Buschur, Marie Flore Pierre, Anne Coletti, Nahida Chakhtoura, Karin L Klingman, Judith Currier, PROMISE (Promoting Maternal and Infant Safety Everywhere) 1077HS Team. Adverse Pregnancy Outcomes Among Women Who Conceive on Antiretroviral Therapy. Clinical Infectious Diseases. 2019. 68: 273-279. PMID: 29868833Year
2019
Journal
Clinical Infectious Diseases
Study
1077HS
Efavirenz pharmacokinetics during pregnancy and infant washout
Citation
Regis Kreitchmann, Stein Schalkwijk, Brookie Best, Jiajia Wang, Angela Colbers, Alice Stek, David Shapiro, Tim Cressey, Mark Mirochnick, David Burger. Efavirenz pharmacokinetics during pregnancy and infant washout. Antiviral Therapy. 2019. 24: 95-103. PMID: 30530925Year
2019
Journal
Antiviral Therapy
Study
P1026S
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Citation
S Nachman, C Alvero, H Teppler, B Homony, AJ Rodgers, BL Graham, T Fenton, LM Frenkel, RS Browning, R Hazra, AA Wiznia, IMPAACT 1066 Study Team. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.. Lancet HIV. 2018. 5: e715-e722. PMID: 30527329Year
2018
Journal
Lancet HIV
Study
P1066
Assessing Psychiatric Symptoms in Youth Affected by HIV: Comparing a Brief Self-Administered Rating Scale with a Structured Diagnostic Interview.
Citation
M Chernoff, KN Angelidou, PL Williams, P Brouwers, M Warshaw, S Nachman, IMPAACT P1055 Study Team. Assessing Psychiatric Symptoms in Youth Affected by HIV: Comparing a Brief Self-Administered Rating Scale with a Structured Diagnostic Interview.. Journal of Clinical Psychology in Medical Settings. 2018. 25: 420-428. PMID: 29460107Year
2018
Journal
Journal of Clinical Psychology in Medical Settings
Study
P1055
HIV Testing Uptake among Household Contacts of Multidrug-resistant Tuberculosis Index Cases in Eight Countries
Citation
Valarie Opollo, Xingye Wu, Michael Hughes, Susan Swindells, Amita Gupta, Anneke Hesseling, Gavin Churchyard, Soyeon Kim, Richard Lando, Rodney Dawson, Vidya Mave, Alberto Mendoza, Pedro Gonzales, N Kumarasamy, Christelle Van Niekerk, Francesca Conradie, Justin Shenje, Sandy Nerette Fontain, Anthony Garcia-Prats, Aida Asmelash, Tim Cressey, Debra Peters, Rosie Mngqibisa, Ana Cristina Garcia Ferreira, Elisha Okeyo, Linda Naini, Lynne Jones, Betsy Smith, NS Shah. HIV Testing Uptake among Household Contacts of Multidrug-resistant Tuberculosis Index Cases in Eight Countries. International Journal of Tuberculosis and Lung Disease. 2018. 1: 1443-1449. PMID: 30606316Year
2018
Journal
International Journal of Tuberculosis and Lung Disease
Study
IMPAACT 2003/ACTG 5300
Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood
Citation
Jincheng Yang, Mina Nikanjam, Brookie M Best, Jorge Pinto, Ellen G Chadwick, Eric S Daar, Peter L Havens, Natella Rakhmanina, Edmund V Capparelli. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. Journal of Clinical Pharmacology. 2018. 58: 1604-1617. PMID: 30252146Year
2018
Journal
Journal of Clinical Pharmacology
Study
P1030, P1038, P1083
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial
Citation
Risa M Hoffman, Konstantia Nadia Angelidou, Sean S Brummel, Friday Saidi, Avy Violari, Dingase Dula, Vidya Mave, Lee Fairlie, Gerhard Theron, Moreen Kamateeka, Tsungai Chipato, Benjamin H Chi, Lynda Stranix-Chibanda, Teacler Nematadzira, Dhayendre Moodley, Debika Bhattacharya, Amita Gupta, Anne Coletti, James A McIntyre, Karin L Kingman, Nahida Chakhtoura, David E Shapiro, Mary Glenn Fowler, Judith S Currier, IMPAACT PROMISE 1077BF/FF Team. Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. HIV Clinical Trials. 2018. 19: 209-224. PMID: 30890061Year
2018
Journal
HIV Clinical Trials
Study
1077BF, 1077FF
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV
Citation
Jeremiah D Momper, Brookie M Best, Jiajia Wang, Edmund V Capparelli, Alice Stek, Emily Barr, Martina L Badell, Edward P Acosta, Murli Purswani, Elizabeth Smith, Nahida Chakhtoura, Kyunghun Park, Sandra Burchett, David E Shapiro, Mark Mirochnick, IMPAACT P1026s Protocol Team. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. AIDS. 2018. 32: 2507-2516. PMID: 30134297Year
2018
Journal
AIDS
Study
P1026S
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
Citation
Stein Schalkwijk, Rob Ter Heine, Angela C Colbers, Alwin D R Huitema, Paolo Denti, Kelly E Dooley, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, Mark Mirochnick, David M Burger. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clinical Pharmacokinetics. 2018. 57: 1421-1433. PMID: 29520730Year
2018
Journal
Clinical Pharmacokinetics
Study
P1026S